SCHEMBL2862973

SCHEMBL2862973

CC(=O)N(CCCCN(CCCn1c(=O)[nH]c2ccccc2c1=O)C(C)=O)CCCNC(=O)c1ccc(O)cc1

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.55
HPGD P15428 3/20 0.55
MAPK10 P53779 1/20 0.55
GAA P10253 6/20 0.53
HSD17B10 Q99714 5/20 0.53
KDM4E B2RXH2 4/20 0.53
GLA P06280 3/20 0.53
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
MPO P05164 2/20 0.52
MAPT P10636 5/20 0.51
ALDH1A1 P00352 3/20 0.51
TP53 P04637 3/20 0.49
POLB P06746 1/20 0.49
RXFP1 Q9HBX9 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
HTT P42858 1/20 0.48
MAPK1 P28482 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2863172 0.95 LMNA (0.52) LMNAHPGDMAPK10GAAHSD17B10
SCHEMBL2862784 0.95 LMNA (0.52) LMNAHPGDMAPK10GAAHSD17B10
SCHEMBL17598944 0.89 LMNA (0.48) LMNAHPGDMAPK10GAAHSD17B10
SCHEMBL2864263 0.85 MPO (0.69) HPGDGAAHSD17B10KDM4EGLA
SCHEMBL2859666 0.84 MPO (0.71) LMNAHPGDMAPK10GAAHSD17B10
SCHEMBL2864602 0.83 LMNA (0.58) LMNAHPGDMAPK10GAAHSD17B10
SCHEMBL2854670 0.83 MPO (0.63) LMNAHPGDMAPK10GAAHSD17B10
Otaplimastat SCHEMBL30083452 0.83 MPO (0.60) LMNAHPGDMAPK10GAAHSD17B10
Otaplimastat SCHEMBL2858656 0.83 MPO (0.60) LMNAHPGDMAPK10GAAHSD17B10
SCHEMBL2854663 0.81 MPO (0.67) HPGDGAAHSD17B10KDM4EGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9290480-B2 Quinazoline-2,4-dione derivative, and medical compositions for the prophylaxis and treatment of cranial nerve disease containing the same Shin Poong Pharmaceuticals Co., Ltd. (KR) 2016-03-22 US claimed
US-20130102622-A1 Novel Quinazoline-2,4-Dione Derivative, and Medical Compositions for the Prophylaxis and Treatment of Cranial Nerve Disease Containing the Same SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2013-04-25 US claimed
US-8404696-B2 Quinazoline-2,4-dione derivative, and medical compositions for the prophylaxis and treatment of cranial nerve disease containing the same SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2013-03-26 US claimed
EP-2239257-B1 NOVEL QUINAZOLINE-2,4-DIONE DERIVATIVE, AND MEDICAL COMPOSITIONS FOR THE PROPHYLAXIS AND TREATMENT OF CRANIAL NERVE DISEASE CONTAINING THE SAME SHIN POONG PHARMACEUTICAL CO LTD (KR) 2012-06-06 EP claimed
US-20100311769-A1 NOVEL QUINAZOLINE-2,4-DIONE DERIVATIVE, AND MEDICAL COMPOSITIONS FOR THE PROPHYLAXIS AND TREATMENT OF CRANIAL NERVE DISEASE CONTAINING THE SAME SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2010-12-09 US claimed
EP-2239257-A2 NOVEL QUINAZOLINE-2,4-DIONE DERIVATIVE, AND MEDICAL COMPOSITIONS FOR THE PROPHYLAXIS AND TREATMENT OF CRANIAL NERVE DISEASE CONTAINING THE SAME Shin Poong Pharmaceutical Co. Ltd. (KR) 2010-10-13 EP claimed
US-9290480-B2 Quinazoline-2,4-dione derivative, and medical compositions for the prophylaxis and treatment of cranial nerve disease containing the same Shin Poong Pharmaceuticals Co., Ltd. (KR) 2016-03-22 US disclosed
US-20130102622-A1 Novel Quinazoline-2,4-Dione Derivative, and Medical Compositions for the Prophylaxis and Treatment of Cranial Nerve Disease Containing the Same SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2013-04-25 US disclosed
US-8404696-B2 Quinazoline-2,4-dione derivative, and medical compositions for the prophylaxis and treatment of cranial nerve disease containing the same SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2013-03-26 US disclosed
EP-2239257-B1 NOVEL QUINAZOLINE-2,4-DIONE DERIVATIVE, AND MEDICAL COMPOSITIONS FOR THE PROPHYLAXIS AND TREATMENT OF CRANIAL NERVE DISEASE CONTAINING THE SAME SHIN POONG PHARMACEUTICAL CO LTD (KR) 2012-06-06 EP disclosed
US-20100311769-A1 NOVEL QUINAZOLINE-2,4-DIONE DERIVATIVE, AND MEDICAL COMPOSITIONS FOR THE PROPHYLAXIS AND TREATMENT OF CRANIAL NERVE DISEASE CONTAINING THE SAME SHIN POONG PHARMACEUTICAL CO., LTD. (KR) 2010-12-09 US disclosed
EP-2239257-A2 NOVEL QUINAZOLINE-2,4-DIONE DERIVATIVE, AND MEDICAL COMPOSITIONS FOR THE PROPHYLAXIS AND TREATMENT OF CRANIAL NERVE DISEASE CONTAINING THE SAME Shin Poong Pharmaceutical Co. Ltd. (KR) 2010-10-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100311769-A1 NOVEL QUINAZOLINE-2,4-DIONE DERIVATIVE, AND MEDICAL COMPOSITIONS FOR THE PROPHYLAXIS AND TREATMENT OF CRANIAL NERVE DISEASE CONTAINING THE SAME AQP4, PMP22, CNTN1 LMNA 1933/4885HPGD 283/4885MAPK10 1362/4885
US-20130102622-A1 Novel Quinazoline-2,4-Dione Derivative, and Medical Compositions for the Prophylaxis and Treatment of Cranial Nerve Disease Containing the Same AQP4, PMP22, CNTN1 LMNA 1933/4885HPGD 283/4885MAPK10 1362/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.